Extensive-Stage Small Cell Lung Cancer and Chemotherapy-Induced Myelosuppression

Types of chemotherapy-induced myelosuppression that typically occur in patients with extensive-stage small cell lung cancer and considerations for treating patients based on risk factors and presentation of adverse events.

Drs Charu Aggarwal and Jared Weiss react to the impact that chemotherapy-induced myelosuppression can have on patients with extensive-stage small cell lung cancer, as well as the overall health system.

Guidance for managing chemotherapy-induced myelosuppressive events in patients with extensive-stage small cell lung cancer based on risk stratification criteria, available therapies, and prophylaxis options.

Pros and cons of strategies used to manage chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

The rationale for using CDK4/6 inhibitors to prevent myelosuppression in patients receiving chemotherapy-containing regimens for extensive-stage small cell lung cancer.

Jared Weiss, MD, of UNC Lineberger Comprehensive Cancer Center, highlights clinical trial data that led to the approval of trilaciclib in patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

Advantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

Jared Weiss, MD, reacts to new measures that increase patient access and provider reimbursement to trilaciclib for patients with extensive-stage small cell lung cancer.

Trials of interest exploring various novel therapies as chemoprotection in patients with solid tumor cancers.